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Osteoporosis is caused by increased bone resorption and decreased bone formation. Inter-
mittent administration of a fragment of Parathyroid hormone (PTH) activates osteoblast-
mediated bone formation and is used in patients with severe osteoporosis. However, the
mechanisms by which PTH elicits its anabolic effect are not fully elucidated. Here we show
that the absence of the homeodomain protein TG-interacting factor 1 (Tgif1) impairs
osteoblast differentiation and activity, leading to a reduced bone formation. Deletion of
Tgif1 in osteoblasts and osteocytes decreases bone resorption due to an increased secretion
of Semaphorin 3E (Sema3E), an osteoclast-inhibiting factor. Tgif1 is a PTH target gene and
PTH treatment failed to increase bone formation and bone mass in Tgif1-deficient mice. Thus,
our study identifies Tgif1 as a novel regulator of bone remodeling and an essential component
of the PTH anabolic action. These insights contribute to a better understanding of bone
metabolism and the anabolic function of PTH.
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Skeletal fragility is a growing medical and socioeconomicburden for aging societies1–3. Bones are constantly dis-mantled and rebuilt by matrix-resorbing osteoclasts and
bone-forming osteoblasts. This well-balanced process of bone
remodeling supports the maintenance of bone quality and
stability2,4.
Osteoblasts arise from mesenchymal precursor cells and can
differentiate into matrix-entrapped osteocytes4. Differentiation of
osteoblasts is controlled by signaling pathways and regulatory
factors, including T-cell factor/lymphoid enhancing factor
(Tcf/Lef), Osterix (Osx/Sp7), Runt-related transcription factor 2
(Runx2), zinc finger proteins and homeodomain proteins5–8.
Osteoblasts and osteocytes provide activation signals to osteo-
clasts via receptor activator of nuclear factor-κB ligand (RANKL),
which binds to the RANK receptor on pre-osteoclasts and mature
osteoclasts9,10. Osteoblasts can also provide negative signals
to osteoclasts by secreting osteoprotegerin (OPG), a soluble
RANKL decoy receptor, thereby inhibiting the RANKL–RANK
interaction and subsequent osteoclast activation10,11. In addition
to the RANKL/OPG system, interleukins (ILs), insulin-like
growth factors (IGFs) and Ephrin signaling also participate in
the osteoblast–osteoclast crosstalk12,13.
During aging, bone remodeling often becomes unbalanced with
bone resorption exceeding bone formation. This can cause
osteoporosis characterized by a decrease in bone mass and bone
mineral density (BMD), and fragility fractures3,14. Specific
osteoporosis treatment includes the reduction of bone resorption
using bisphosphonates (e.g., Alendronate, Risedronate or Zole-
dronate) or an antibody against RANKL (Denosumab)14. An
alternative approach is to increase bone formation, for instance,
by the intermittent administration of a recombinant fragment of
human parathyroid hormone containing the first 34 amino acids
(hPTH 1–34, Teriparatide, hereafter referred to PTH)2,14,15. If
administered intermittently in a pharmacological manner, PTH
stimulates bone remodeling by increasing the activity of osteo-
blasts and osteoclasts. This leads to a net increase in bone mass
and BMD, thereby reducing the fracture risk15–17.
Bone formation is also strongly activated by the canonical Wnt
signaling pathway, which was uncovered from rare genetic dis-
eases7. For instance, a gain-of-function mutation of the Wnt co-
receptor low-density lipoprotein receptor-related protein 5 (LRP5)
causes a high bone mass (HBM) phenotype18,19. Lrp5 is important
for the activation of the canonical Wnt pathway, since binding of
Wnt ligands to Lrp5 or 6 and frizzled co-receptors activate the
signaling cascade. Once activated, β-catenin translocates to the
nucleus and induces the expression of target genes, including
Axin2 and CyclinD17. Inhibition of Lrp5 signaling can be achieved
by the binding of soluble antagonists such as Dickkopf 1 (Dkk1)
and Sclerostin20. Sclerostin, which is encoded by the SOST gene, is
secreted by osteocytes and binds to Lrp4–6 receptors on osteo-
blasts, thereby antagonizing Wnt signaling21–23. Similar to Lrp5,
mutations reducing the expression of the SOST gene were iden-
tified to cause HBM in sclerosteosis and Van Buchem disease24,25.
Supported by these findings, a monoclonal anti-sclerostin anti-
body (Romosozumab) has been developed as a novel bone ana-
bolic therapy, which increases bone mass and strength and
decreases the fracture risk26–29.
The canonical Wnt pathway and the PTH pathway are not
separated and PTH signaling stimulates bone formation by cross-
activating the canonical Wnt signaling using various mechanisms,
including the decrease of Dkk1 and sclerostin expression30–32.
Although great advances have been made in the development of
novel anti-osteoporosis drugs, it is still very important to further
decipher molecular mechanisms underlying the control of phy-
siological and pharmacologically induced bone remodeling to
reach a better understanding of these processes. Here, we identify
the homeodomain protein TG-interacting factor 1 (Tgif1) as a
novel Wnt and PTH target gene and a crucial regulator of
osteoblast function. Absence of Tgif1 impairs osteoblast differ-
entiation in vitro and osteoblast activity and bone formation
in vivo. Deletion of Tgif1 in osteoblasts and osteocytes also
decreases bone resorption due to an increased secretion of the
osteoclast-inhibiting factor Semaphorin 3E (Sema3E)33. Although
the bone anabolic function of Wnt signaling is unaffected by the
absence of Tgif1, PTH treatment fails to increase bone mass in
mice lacking Tgif1 in the osteoblast lineage. This is at least in part
due to an incomplete decrease in the expression of the myocyte
enhancer factor 2c (Mef2c) and subsequent sclerostin expression
upon PTH treatment. Thus, our study identifies Tgif1 as a novel
regulator of bone remodeling and an essential component of the
PTH anabolic signaling. These insights contribute to the better
understanding of steady state and pharmacologically activated
bone remodeling.
Results
Deletion of Tgif1 impairs bone remodeling. Homeodomain
proteins are transcriptional regulators that play important roles in
osteoblast differentiation and bone formation5,6. To uncover
homeodomain proteins with a yet unknown function in the
osteoblast lineage, we performed RNA-sequencing in mouse bone
marrow stromal cells (BMSCs) and identified Tgif1 as the most
abundantly expressed homeodomain protein of unknown func-
tion in bone (Fig. 1a). To elucidate the role of Tgif1 in bone, we
obtained osteoblasts from mice with a germline deletion of Tgif1
(Tgif1−/−)34. Using in vitro differentiation assays, we determined
that loss of Tgif1 in osteoblasts decreased the alkaline phospha-
tase (ALP) activity (Fig. 1b) and the Alp expression (Fig. 1c).
Furthermore, Tgif1 deficiency impaired the matrix mineralization
(Fig. 1d) and reduced the osteocalcin expression (Fig. 1e),
demonstrating that Tgif1 promotes osteoblast differentiation.
To rule out the possibility that Tgif2, a paralog of Tgif135, is
increased in the absence of Tgif1 in a compensatory manner, we
quantified the expression of Tgif2 in Tgif1−/− osteoblasts. Tgif2
expression was lower than the expression of Tgif1 (Supplemen-
tary Fig. 1a) and unchanged in the absence of Tgif1 (Supple-
mentary Fig. 1a, b), suggesting that the lack of Tgif1 is not
compensated by an increased expression of Tgif2.
In order to elucidate the role of Tgif1 in bone remodeling, we
investigated the bone phenotype of Tgif1-deficient mice. Histo-
morphometric analysis revealed that the absence of one or both
alleles of Tgif1 did not change bone mass (bone volume per tissue
volume (BV/TV)) in the proximal tibiae or the lumbar spine
(Fig. 1f, g and Supplementary Fig. 2a, b and Supplementary
Tables 1 and 2). However, osteoblast parameters including the
number of osteoblasts per bone surface (N.Ob/BS), osteoblast
surface per bone surface (Ob.S/BS) and functional indices like the
mineral appositions rate (MAR) and the bone formation rate per
bone surface (BFR/BS) were significantly decreased in Tgif1−/−
mice compared to control littermates (Fig. 1f insets, 1g and
Supplementary Tables 1 and 2). The greatly impaired osteoblast-
mediated bone formation was accompanied by a significant
reduction of osteoclast parameters, including the number of
osteoclasts per bone surface (N.Oc/BS) and the osteoclast surface
per bone surface (Oc.S/BS) (Fig. 1g and Supplementary Tables 1
and 2). This led to a reduced eroded surface per bone surface
(ES/BS) and therefore to a diminished bone resorption (Fig. 1g and
Supplementary Tables 1 and 2). The combined reduction of bone
formation and bone resorption caused a gender-independent low-
turnover bone phenotype. Thus, these findings confirm the positive
role of Tgif1 for osteoblast function and bone formation and
demonstrate that Tgif1 is a novel regulator of bone remodeling.
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To further investigate these findings, we targeted the deletion
of Tgif1 to the osteoblast lineage by crossing mice carrying the
Tgif1 gene flanked by loxP sites (Tgif1fl/fl)34 with mice expressing
the Cre recombinase downstream of the Osterix (Osx/Sp7)
promoter (Osx-CreTg)36 or the Dentin matrix protein 1 (Dmp1)
regulatory element (Dmp1-CreTg)37. Lack of Tgif1 in osteoblasts
in Osx-CreTg;Tgif1fl/fl or in Dmp1-CreTg;Tgif1fl/fl mice
recapitulated the bone phenotype of Tgif1−/− mice (Fig. 1h, i
and Supplementary Fig. 2c–h and Supplementary Tables 3 and 4),
confirming that Tgif1 in mature osteoblasts and osteocytes is
required for the full activation of bone remodeling.
Semaphorin 3E impairs osteoclast differentiation. Interestingly,
histomorphometric analysis of bones from mice bearing an
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Fig. 1 Deletion of TG-interacting factor 1 (Tgif1) in osteoblasts reduces osteoblast differentiation and bone remodeling. a Homeodomain proteins listed
according to their expression in mouse bone marrow stromal cells (BMSCs) during osteoblast differentiation. Expression is indicated as mean values
(arbitrary units) with the respective standard deviation (s.d.) (N= 3). The first 10 genes are marked in shades of red and the remaining 10 genes are
presented in shades of blue. b Staining of alkaline phosphatase (ALP) activity after in vitro differentiation of Tgif1+/+ and Tgif1−/− calvarial osteoblasts for
14 days (representative image of 3 experiments) and c relative Alp mRNA expression (N= 4). d Determination of matrix mineralization by Alizarin Red
staining after 21 days of differentiation (representative image of 3 experiments) and e relative osteocalcin (Ocn) mRNA expression (N= 4). f Representative
images of proximal tibiae of 8-week-old male mice with the genotypes Tgif1+/+, Tgif1+/− and Tgif1−/− after von Kossa staining and fluorescence double
labeling to visualize bone formation (insets). g Histomorphometric analysis of the proximal tibiae of 8-week-old male Tgif1+/+, Tgif1+/− and Tgif1−/− mice
(N= 10, 6 and 8). BV/TV bone volume/tissue volume, MS/BS mineralizing surface/bone surface, BFR/BS bone formation rate/bone surface, MAR mineral
apposition rate, OS/BS osteoid surface/bone surface, Ob.S/BS osteoblast surface/bone surface, N.Ob/BS number of osteoblasts/bone surface, ES/BS
eroded surface/bone surface, Oc.S/BS osteoclast surface/bone surface, N.Oc/BS number of osteoclasts/bone surface. *p<0.05, **p<0.01, ***p<0.001 vs.
Tgif1+/+, #p<0.05, ##p<0.01, ###p<0.001 vs. Tgif1+/−. h Representative images of proximal tibiae of 8-week-old male mice with the genotypes Dmp1-
Cre−;Tgif1fl/fl and Dmp1-CreTg;Tgif1fl/fl after von Kossa staining and fluorescence double labeling to visualize bone formation (insets). i Histomorphometric
analysis of the proximal tibiae of 8-week-old male Dmp1-Cre−;Tgif1fl/fl and Dmp1-CreTg;Tgif1fl/fl mice (N= 9, 8). For abbreviations see g. **p<0.01,
***p<0.001 vs. Dmp1-Cre-;Tgif1fl/fl. Scale bars indicate 1 mm (black) and 50 μm (white) f, h. Error bars represent the s.e.m. Two-tailed Student's t-test was
used to compare two groups c, e, i, and analysis of variance (ANOVA) followed by Newman–Keuls post-hoc analysis was used to compare three groups g
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osteoblast-targeted deletion of Tgif1 revealed a suppression of
osteoclast differentiation and bone resorption (Fig. 1i and Sup-
plementary Fig. 2d and Supplementary Table 3 and 4), suggesting
a Tgif1-dependent signaling between osteoblasts and osteoclasts.
Indeed, in an in vitro co-culture system, Tgif1−/− osteoblasts were
impaired to support osteoclast differentiation demonstrated by a
reduced number of tartrate-resistant acid phosphatase (TRAP)-
positive multinucleated cells (Fig. 2a, b).
Osteoblast-derived factors are well established to contribute to
the differentiation and function of osteoclasts12,38,39. The most
prominent system includes RANKL, which emerges from
osteoblasts and binds to its receptor RANK on osteoclasts and
can be antagonized by OPG9,10. We therefore quantified the serum
concentration of RANKL and OPG in Tgif1−/− and Tgif1+/+
mice, and calculated the resulting RANKL/OPG ratio but did not
detect any differences (Fig. 2c). In addition, the expression of
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Fig. 2 TG-interacting factor 1 (Tgif1)-deficient osteoblasts inhibit osteoclast differentiation in a Semaphorin 3E (Sema3E)-dependent manner. a Tartrate-
resistant acid phosphatase (TRAP) staining of osteoclasts (OC) in an osteoblast–osteoclast co-culture with Tgif1+/+ osteoclasts and Tgif1+/+ or Tgif1−/−
osteoblasts (OB) (representative image of 3 experiments). b Quantification of TRAP-positive multinucleated cells (MNCs) with a minimum of three nuclei
(N= 3). c Serum concentration of RANKL (receptor activator of nuclear factor NF-κB ligand) and OPG (osteoprotegerin) in Tgif1+/+ and Tgif1−/− mice
measured by enzyme-linked immunosorbent assay (ELISA) and calculation of the RANKL/OPG ratio (N= 10, 6). d Fold increase in proteins secreted by
Tgif1−/− calvarial osteoblasts relative to Tgif1+/+ calvarial osteoblasts as determined by stable isotope labeling by amino acids in cell culture (SILAC;
N= 4). e Relative Sema3EmRNA expression in calvarial osteoblasts harvested from Tgif1+/+ and Tgif1−/−mice (N=6, 6). b, d, e *p<0.05 **p<0.01 vs. Tgif1
+/+ osteoblasts. f Immunoblot of Sema3E protein expression in calvarial osteoblasts obtained from Tgif1+/+ and Tgif1−/− mice. Immunoblot for Actin was
used as a loading control. Normalized fold expression and molecular weight in kilo Dalton (kDa) are indicated (representative image of 4 experiments).
g Osteoclast differentiation in a co-culture system with Tgif1+/+ OC and Tgif1+/+ and Tgif1−/− OB transfected with scrambled (scr) control siRNA or
Sema3E siRNA (siSema3E) at indicated concentrations (representative image of 4 experiments) and h quantification of TRAP-positive MNCs (N= 12).
*p<0.05, **p<0.01, ***p<0.001 vs. Tgif1+/+ scr., ##p<0.01, ###p<0.001 vs. Tgif1−/− scr. Scale bars indicate 100 μm a, g. Error bars represent the s.e.m.
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Rankl and Opg was identical in tibiae, calvarial osteoblasts and in
long bone osteoblasts from Tgif1−/− mice and control littermates
with no change in the Rankl/Opg ratio (Supplementary Fig. 3a–c).
Next, we investigated the expression of genes encoding additional
factors known to regulate the osteoblast–osteoclast interaction,
including Ephrin type-B receptor 2 and 4 (Eph2B, Eph4B), Ephrin
2B40, ILs (IL-1, IL-6, IL-11, IL-18)41, IGFs (IGF-1, IGF-2) and
of their respective binding proteins (Igfbp-2, Igfbp-3, Igfbp-5)13 but
did not determine an altered expression in Tgif1−/− mice
(Supplementary Fig. 3d). In order to identify the secreted factor
by which Tgif1−/− osteoblasts suppress osteoclast differentiation,
we performed an unbiased secretome analysis using stable isotope
labeling by amino acids in cell culture (SILAC). Among the factors
that were significantly increased in Tgif1−/− osteoblasts (Fig. 2d),
we focused on Sema3E, a class III semaphorin previously shown to
inhibit osteoclast formation33. Gene expression and immunoblot
analysis confirmed a higher expression of Sema3E in Tgif1−/−
osteoblasts (Fig. 2e, f), suggesting that Tgif1 inhibits Sema3E
expression to allow normal osteoclast differentiation. Indeed,
small interfering RNA (siRNA)-mediated inhibition of Sema3E
expression in Tgif1−/− osteoblasts (Supplementary Fig. 3e)
restored the differentiation of co-cultured osteoclasts to the level
of control (Fig. 2g, h), demonstrating that Tgif1 deficiency
increases the expression of the osteoblast–osteoclast signaling
molecule Sema3E, leading to an inhibition of osteoclast
differentiation.
Tgif1 deficiency in bone does not alter Wnt signaling. Since
canonical Wnt signaling is a strong stimulator of bone formation7
and because Tgif1 has been implicated in oncogenic Wnt sig-
naling, we hypothesized that Tgif1 could be an important reg-
ulator of this pathway in bone42,43. To test this hypothesis, we
stimulated osteoblasts with Wnt3a and determined an increase in
Tgif1 protein expression (Fig. 3a), thereby establishing Tgif1 as a
canonical Wnt target gene. Analysis of the 2.2 kb upstream region
of the Tgif1 promoter revealed the presence of putative Tcf/Lef
binding sites, suggesting a transcriptional mechanism underlying
the increase in Tgif1 expression upon Wnt stimulation. Indeed, a
reporter gene assay revealed an activation of the Tgif1 promoter
in osteoblasts upon Wnt3a stimulation (Fig. 3b). Furthermore,
reporter gene activation in osteoblasts by Wnt3a (Fig. 3c) or co-
transfection with β-catenin (Fig. 3d) was abolished using trun-
cated promoter fragments lacking Tcf/Lef binding sites. These
findings demonstrate that Tgif1 is a Wnt target gene.
Next, we determined if Tgif1 affects the Wnt pathway activity.
To address this question, we crossed reporter mice expressing the
β-galactosidase in the presence of activated β-catenin (BAT-
GALTg) with Tgif1−/− mice (BAT-GALTg;Tgif1−/−). Expression
of the β-galactosidase in BAT-GALTg;Tgif1−/− reporter mice as a
surrogate for in vivo Wnt activity was unchanged compared to
control mice, suggesting that Tgif1 might not play a functional
role in Wnt signaling in bone (Fig. 3e). To ensure the
functionality of the system, we harvested BMSCs from long
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bones of BAT-GALTg;Tgif1+/+ and BAT-GALTg;Tgif1−/− mice
and treated the cells with vehicle or PTH, which is known
to cross-activate Wnt signaling2. Quantification of the
β-galactosidase-positive cells revealed a significant induction of
Wnt signaling in BMSCs of both genotypes (Fig. 3f), confirming
that the pathway can be activated in this system. The lack of
a regulatory role of Tgif1 in Wnt signaling in bone was further
confirmed by an unchanged expression of the Wnt target genes
CyclinD1 and Axin2 in bones of Tgif1−/− mice compared to
control littermates (Fig. 3g, h). Furthermore, Wnt3a activated
the TopFlash reporter assay equally in Tgif1−/− and control
osteoblasts (Fig. 3i), indicating that in bone the canonical Wnt
pathway activity is independent of Tgif1 under steady-state
conditions.
Tgif1 is dispensable for the Wnt-mediated gain in bone mass.
To test the possibility that the absence of Tgif1 affects bone
remodeling in response to Wnt activation, we injected Tgif1−/−
mice and control animals with an antibody against the Wnt
pathway inhibitor sclerostin (Scl-Ab). Quantification of the bone
mass revealed that the Scl-Ab-mediated increase in BV/TV was
comparable between genotypes (Fig. 4a, b and Supplementary
Table 5). Next, we crossed two knock-in mouse lines each bearing
a HBM mutation of Lrp5 that are equivalent to mutations found
in humans (G170V and A213V)44 with Tgif1−/− animals to
constitutively activate Wnt signaling. Consistently, the gain in
bone mass in Lrp5G170V/+ and Lrp5A213V/+ mice was indepen-
dent of Tgif1 (Supplementary Tables 6 and 7). However, a
detailed histomorphometric analysis uncovered that activation of
the Wnt pathway in response to a Scl-Ab treatment and in mice
carrying the G170V HBM mutation did increase all osteoblast
parameters (OS/BS, Ob.S/BS, N.Ob/BS) and the bone formation
rate (BFR/BS) more pronounced in Tgif1−/− mice than in control
animals (Fig. 4b and Supplementary Tables 5 and 6). Although
the exact reason for this observation remains to be elucidated,
it could be due to a higher responsiveness on the basis of a low
bone turnover remodeling in Tgif1−/− mice. However, this effect
on osteoblasts did not yield a greater increase in bone mass. Thus,
these data confirm that Tgif1 is dispensable to elicit the Wnt-
induced increase in bone mass.
PTH induces Tgif1 expression through AP1 signaling. Upon
binding of PTH to its G protein-coupled receptor PTHR1, the
Gsα-linked cAMP-dependent protein kinase A (PKA) signaling
pathway becomes activated45,46. Activated PKA induces phos-
phorylation of the cAMP response element-binding protein
(CREB) in the cytoplasm, which translocates to the nucleus and
initiates the expression of target genes45,46. Members of the
activator protein 1 (AP1) family are increased in their expression
upon PTH stimulation and participate in regulating osteoblast
function and bone formation47. Osteoblast activation by PTH not
only increases bone formation but also the expression of RANKL,
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which activates osteoclast-mediated bone resorption and causes a
high turnover bone remodeling2. Since the histomorphometric
analysis of Tgif1−/−, Osx-CreTg;Tgif1fl/fl and Dmp1-CreTg;Tgif1fl/fl
mice revealed a low-turnover bone phenotype (Fig. 1f–i and
Supplementary Fig. 2c, d and Supplementary Tables 1–4), we
hypothesized that Tgif1 might be a component of the PTH sig-
naling cascade. To investigate this hypothesis, we first determined
if Tgif1 is a PTH target gene. PTH stimulation increased the
Tgif1 protein abundance in calvarial osteoblasts and the Tgif1
mRNA expression in differentiating cells of the osteocyte-derived
SW3 cell line (Fig. 5a, b). Furthermore, Tgif1 expression in bones
of mice lacking the PTHR1 in mature osteoblasts and osteocytes
(Dmp1-CreTg;PTHR1fl/fl)48 was unchanged under basal condi-
tions, while PTH increased Tgif1 expression in control but
not in Dmp1-CreTg;PTHR1fl/fl animals (Fig. 5c). In a reciprocal
experiment we determined that the constitutive activation of
the PTHR1 in mature osteoblasts and osteocytes (Dmp1-
caPTHR1)49 increased the Tgif1 expression (Fig. 5d) as did the
stimulation of calvarial osteoblasts with the PKA activator for-
skolin (Fig. 5e), demonstrating that Tgif1 expression is induced
by the PTH–PKA–pCREB pathway.
To further elucidate the mechanisms by which PTH induces
Tgif1 expression, we analyzed the 2.2 kb region of the Tgif1
promoter. This analysis revealed the presence of an AP1 binding
site upstream of the Tgif1 transcription start site (Fig. 5f),
suggesting that PTH might increase Tgif1 expression via
AP1 signaling. Indeed, PTH increased the activity of the 2.2 kb
fragment of the Tgif1 promoter in osteoblasts (Fig. 5g).
Progressive truncation of the Tgif1 promoter eliminating the
AP1 binding site (Fig. 5h) and its specific mutation (Fig. 5f, i)
abolished the reporter gene activation, demonstrating that PTH
induces Tgif1 through PKA–pCREB–AP1 signaling.
PTH increases bone mass in a Tgif1-dependent manner. Since
Tgif1 is a PTH target gene downstream of the
PKA–pCREB–AP1 signaling cascade, we proposed that Tgif1
might be involved in the increase in bone mass in response to
PTH. To explore this hypothesis, we injected 8-week-old Tgif1−/−
mice and control littermates with PTH or vehicle intermittently
for 4 weeks. In control animals, PTH strongly increased all
osteoblast parameters (OS/BS, Ob.S/BS and N.Ob/BS) and bone
formation (MS/BS, BFR/BS and MAR) as well as osteoclast
parameters (Oc.S/BS and N.Oc/BS) and bone resorption (ES/BS),
leading to a high bone mass (BV/TV) phenotype (Supplementary
Fig. 4a, b and Supplementary Table 8). In Tgif1−/− mice, PTH
had a mild effect on osteoblast parameters and bone formation
(OS/BS, Ob.S/BS, N.Ob/BS, BFR/BS and MAR), while the fre-
quency of mineralizing surfaces per bone surface (MS/BS)
remained unchanged. PTH also increased the number of osteo-
clasts per bone surface (N.Oc/BS) as well as the frequency of
eroded surfaces per bone surface (ES/BS) and therefore bone
resorption in Tgif1−/− mice. However, these effects were mod-
erate compared to control littermates and, most importantly, did
not yield an increase in bone mass (BV/TV) (Supplementary
Fig. 4a, b and Supplementary Table 8).
To test whether PTH increases bone mass in mice bearing
a Tgif1 deletion in the osteoblast lineage, we injected PTH for
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4 weeks into 8-week-old Dmp1-CreTg;Tgif1fl/fl mice and control
littermates. Again, in control animals PTH strongly increased all
osteoblast (OS/BS, Ob.S/BS and N.Ob/BS) and osteoclast
parameters (Oc.S/BS and N.Oc/BS) as well as bone formation
(MS/BS, BFR/BS and MAR) and bone resorption (ES/BS) in
the context of a highly activated bone remodeling with the
consequence of a significant increase in bone mass (BV/TV)
(Fig. 6a, b and Supplementary Table 9). In Dmp1-CreTg;Tgif1fl/fl
mice, this effect was attenuated in response to PTH treatment,
resulting in a similar phenotype seen in Tgif1−/− mice. For
instance, in contrast to Tgif1−/− animals the bone formation rate
per bone surface (BFR/BS), the mineral apposition rate (MAR)
and the number of osteoblasts per bone surface (N.Ob/BS) were
not increased in Dmp1-CreTg;Tgif1fl/fl mice in response to PTH.
Consistently, bone mass (BV/TV) was also not changed in Dmp1-
CreTg;Tgif1fl/fl mice (Fig. 6a, b and Supplementary Table 9). These
findings support the notion that Tgif1 is a critical component of
the PTH-mediated increase in bone formation and bone mass
accrual.
PTH reduces sclerostin expression in part through Tgif1. The
bone anabolic effect of PTH is in part mediated through cross-
activation of other pathways including canonical Wnt
signaling31,32,46,50,51. For instance, stimulation of osteoblasts and
osteocytes with PTH decreases the expression of the canonical
Wnt inhibitors Dkk1 and sclerostin, the product of the SOST
gene30,31,52,53. Since the Wnt pathway is a strong inducer of bone
formation15, antagonizing inhibitors of this pathway leads to an
increase in bone mass. To investigate whether Tgif1 is implicated
in the PTH-mediated cross-activation of the Wnt pathway, we
quantified the expression of Dkk1 and sclerostin in the long
bones of Tgif1−/− mice and control littermates 4 h after injection
of PTH or vehicle. Gene expression analysis revealed that PTH
fully reduced the expression of Dkk1 in bones of Tgif1−/− mice
and control littermates (Fig. 7a), while the expression of Sost
mRNA was only partially and not statistically significantly
reduced in mice lacking Tgif1 (Fig. 7b). To confirm this obser-
vation, we performed immunohistochemistry to detect the
abundance of sclerostin in the bones of mice treated with PTH.
Consistent with the results of the gene expression analysis,
sclerostin protein expression in osteocytes was fully abrogated by
PTH in control animals and only partially reduced in Tgif1−/−
mice (Fig. 7c). These findings demonstrate that Tgif1 in mature
osteoblasts and osteocytes is necessary for the full PTH-mediated
inhibition of sclerostin expression.
To unravel the molecular mechanism by which Tgif1
contributes to the suppression of sclerostin expression, we
analyzed the 8 kb upstream region of the Sost promoter and
identified 11 putative sites to which Tgif1 could bind (Supple-
mentary Fig. 5a). Tgif1 forms complexes with other factors and
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represses gene transcription54. We therefore hypothesized that
PTH might increase the Sost promoter occupancy by Tgif1 and
attenuate its activity. To test this hypothesis, we performed
chromatin immunoprecipitation (ChIP) of Tgif1 in the OCY454
osteocyte-like cell line 2 h after incubation with PTH or vehicle.
The ChIP assays revealed that Tgif1 associates with all sites
investigated, except binding sites 8 and 10 (Supplementary
Fig. 5b). Binding to site 9 was detectable but did not reach
significance (Supplementary Fig. 5b). In contrast to our
hypothesis, treatment with PTH caused a dissociation of Tgif1
from all sites with the exception of sites 7 and 9 where no
significance was reached (Supplementary Fig. 5b). As a positive
control, binding of Tgif1 to the promoter of retinoic acid receptor
alpha (Rar alpha) and its dissociation upon PTH treatment
was confirmed (Supplementary Fig. 5b)55. These observations
suggest that Tgif1 might not have a suppressive effect on the
Sost promoter activity in response to PTH treatment and that
other mechanisms might exist.
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In osteocytes, Mef2 transcription factors activate a distant
enhancer of the SOST gene corresponding to the region that is
deleted in Van Buchem disease32. Furthermore, PTH-mediated
inhibition of sclerostin expression in response to PTH stimulation
is largely due to a decrease in Mef2c expression32. Interestingly,
while the distal enhancer of the SOST gene does not contain Tgif1
consensus sequences, the Mef2c promoter contains several Tgif1
binding sites. This indicates that Tgif1 might contribute to
the control of sclerostin expression in an indirect manner by
participating in the repression of Mef2c transcription in response
to PTH treatment. Indeed, PTH suppressed Mef2c mRNA
expression and protein abundance to a much lesser extent in
Tgif1-deficient cells (Supplementary Fig. 6a, b) compared to
controls (Fig. 7d, e). To determine the functional relevance of this
observation, we analyzed the activity of a gene reporter construct
containing the Mef2-responsive distal enhancer element of the
human SOST gene32. Consistent with our findings, PTH strongly
suppressed the reporter gene activity in control cells but to a
significantly lower degree in cells in which the expression of Tgif1
had been restricted (Fig. 7f), demonstrating the functional role of
Tgif1 in regulating the SOST gene activity.
In summary, in response to PTH treatment, Tgif1 dissociates
from the SOST promoter and inhibits the expression of Mef2c.
Due to a reduced abundance of Mef2c, a distant enhancer
element of the SOST gene containing Mef2c binding sites
becomes less activated, causing a decrease in sclerostin expression
and an increase in bone formation. In the absence of Tgif1, this
regulatory cascade is disturbed, leading to an impaired decrease of
sclerostin expression in response to PTH treatment and a lower
bone formation. Thus, Tgif1 is an important mediator of the gain
in bone mass in response to PTH treatment.
Discussion
In this study, we identified Tgif1 as a novel stimulator of osteo-
blast differentiation and function. Bone remodeling depends on
Tgif1, since absence of Tgif1 in osteoblasts causes low bone
turnover due to a decreased osteoblast function and bone for-
mation. The impaired bone formation is accompanied by an
osteoblast-mediated decrease in osteoclast activity and bone
resorption. Since the amount of bone resorbed equals the amount
of bone formed, bone mass is unchanged in Tgif1-deficient mice.
Interestingly, osteoclast differentiation and function is reduced
upon deletion of Tgif1 in osteoblasts. After changes in the
RANKL/OPG system, in Ephrin signaling and in the expression
of interleukins and insulin-like growth factors were excluded,
Sema3E was found to be highly expressed by Tgif1−/− osteoblasts
and to mediate the suppression of osteoclast differentiation.
Although an osteoblast-targeted deletion of Sema3E is needed to
determine whether this alleviates the reduced bone resorption in
mice lacking Tgif1 in osteoblasts, our findings underscore the
important function of Sema3E in bone cell interaction.
In breast cancer, Tgif1 expression correlated with a poor
prognosis and supported the Wnt1-driven cancer development42.
In colorectal cancer, Tgif1 is indispensable for canonical Wnt
activation and promotes the disease through Wnt activation43.
The role of Tgif1 in oncology let us to speculate whether Tgif1
might also be implicated in Wnt signaling in bone. Consistent
with the findings in cancer cells, Wnt signaling increased Tgif1
expression in osteoblasts. This increase was mediated by β-cate-
nin-Tcf/Lef signaling since eliminating Tcf/Lef binding sites in
the Tgif1 promoter abolished the transcriptional activation. In
contrast to cancer cells, absence of Tgif1 in bone or osteoblastic
cells did not change the basal activity of the Wnt pathway in vitro
or in vivo. We further determined that Tgif1 is dispensable for
Wnt-mediated increase in bone mass. This discrepancy to cancer
might be due to differences in the molecular regulation of Wnt
signaling pathways under malignant versus benign conditions
and suggests that Wnt signaling might function differently in
bone than in other organs.
PTH binds to the PTH/PTHrP receptor (PTHR1), a class II G
protein-coupled receptor that activates several pathways, includ-
ing the Gq/11-linked phosphatidyl inositol-specific phospholipase
C–protein kinase C signaling pathway and the Gsα-linked cAMP-
dependent protein kinase A (PKA) signaling pathway45,46. Our
in vitro and in vivo data demonstrate that Tgif1 expression in
osteoblasts and osteocytes is downstream of the PTHR1. Further
analysis revealed that Tgif1 expression is induced by PKA–CREB
signaling. Downstream of PTHR1, PKA signaling leads to the
phosphorylation of CREB, which induces the expression of AP1
transcription factors45–47. AP1 signaling is a mediator of the
anabolic effect of PTH47. The functional relevance of an AP1
binding site in the Tgif1 promoter was demonstrated using
truncations and a specific mutation in reporter assays. These
experiments establish Tgif1 as a PTH target gene downstream of
the PTHR1–PKA–pCREB–AP1 cascade.
Similar to the Wnt pathway, Tgif1 expression is increased by
PTH treatment. Although Tgif1 is dispensable for the bone
anabolic function of Wnt signaling, we addressed the question of
whether Tgif1 might be implicated in the increase in bone mass
by PTH treatment. This hypothesis was supported by a low-
turnover bone remodeling in the absence of Tgif1, which repre-
sents a somehow opposite phenotype obtained by intermittent
administration of PTH. In a pharmacological context, PTH
augments osteoblast function and bone formation but also the
production of RANKL, thereby activating osteoclasts and bone
resorption2. This causes a high turnover bone remodeling with a
net gain in bone mass. Indeed, daily injections of PTH into mice
with a germline deletion of Tgif1 or a targeted deletion of Tgif1 in
osteoblasts and osteocytes prevented the increase in bone mass
compared to control littermates. However, absence of Tgif1 did
not fully abrogate all effects of PTH on bone remodeling and
some differences were noticed between the two mouse models of
Tgif1 deletion. These findings indicate that Tgif1 contributes to
many but not all effects downstream of PTHR1 signaling. Most
importantly, in the absence of Tgif1 in the osteoblast lineage, the
residual effects of PTH on bone are insufficient for bone mass
accrual.
PTH exerts its bone-forming function also in part through
cross-activation of canonical Wnt signaling46. For instance, PTH
inactivates glycogen synthase kinase-3β (GSK3β)50 and stabilizes
β-catenin51. PTHR1 forms a complex with Lrp6 upon binding of
PTH, thereby disintegrating the destruction complex51. In this
context, Lrp6 in osteoblasts was shown to be essential for the
anabolic effect of PTH51. In osteocytes, PTH reduces the
expression of the Wnt inhibitors Dkk130 and sclerostin49. Inhi-
bition of sclerostin expression in osteocytes is mediated by Mef2
transcription factors that control the activity of a distant enhancer
element of the SOST gene32. In detail, PTH signaling leads to a
PKA-mediated phosphorylation and inhibition of the salt-
inducible kinase 2 (SIK2). This reduces the phosphorylation of
histone deacetylases 4 and 5 (HDAC4/5), which translocate to the
nucleus and inhibit the Mef2c-driven sclerostin expression56.
Evidence for the physiological role of sclerostin inhibition as an
important component of the PTH anabolic effect is provided by
in vivo studies, demonstrating that PTH decreases sclerostin
expression in wild-type mice. Furthermore, the PTH-induced
gain in bone mass was blunted in mice overexpressing or lacking
sclerostin, demonstrating that sclerostin is an important com-
ponent of anabolic PTH signaling57. However, other studies have
shown a normal or even enhanced response to PTH treatment
in SOST knockout mice46. Consistent with these findings, the
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increase in bone mass by PTH in mice overexpressing human
sclerostin under the control of the 8 kb fragment of the Dmp1
promoter was comparable to control littermates58. These con-
troversies might be explainable by the use of transgenes obtained
from different species, the use of various artificial promoter ele-
ments to drive the overexpression or other technical aspects.
Nevertheless, although the exact contribution of the down-
regulation of sclerostin expression in response to PTH is not yet
fully elucidated, this mechanism is likely to be an important
component of the PTH bone anabolic effect.
In order to determine whether the PTH-mediated crosstalk
with the Wnt pathway could be impaired in Tgif1−/− mice in
which PTH treatment did not increase bone mass, we investigated
the Dkk1 and sclerostin expression in bones from Tgif1−/− mice
and control littermates. The basal expression of Dkk1 and
Sost was comparable between Tgif1−/− and control mice. Of
note, PTH treatment suppressed the Dkk1 expression in animals
of both genotypes strongly and equally but the Sost expression
was only partially decreased in Tgif1−/− mice compared to con-
trol littermates. This observation was confirmed in bone sections
at the protein level using immunohistochemistry. Although the
incomplete downregulation of sclerostin expression by PTH
in Tgif1−/− mice was moderate, it might at least in part con-
tribute to the blunted bone anabolic effect of PTH in Tgif1-
deficient mice.
Although Tgif1 physically associates with the Sost promoter, an
inhibitory effect on sclerostin expression is less likely due to the
displacement of Tgif1 from its consensus binding sites in
response to PTH stimulation. However, our findings demonstrate
that Tgif1 contributes to the PTH-mediated repression of Mef2c
expression. By this mechanism, Tgif1 has an indirect inhibitory
effect on sclerostin expression. In the absence of Tgif1, PTH
stimulation reduces Mef2c expression incompletely, allowing the
remaining Mef2c to bind to a distant enhancer element of the Sost
gene, leading to a residual transcriptional activity and sclerostin
expression.
In summary, the PTH–PKA–pCREB–AP1 pathway and
canonical Wnt signaling increase Tgif1 expression in osteoblasts
and osteocytes (Fig. 7g). Tgif1 supports osteoblast differentiation,
function and bone formation. By suppressing the expression of
Sema3E, Tgif1 facilitates bone resorption and therefore physio-
logical bone remodeling. In osteocytes, Tgif1 contributes to the
inhibition of Mef2c expression and thereby to the decrease of
sclerostin expression in response to PTH treatment. Thus, our
study identified Tgif1 as a novel regulator of bone remodeling and
an essential component of the PTH anabolic action.
Methods
Mouse models. Mice with a germline deletion of Tgif1 and a loxP-flanked Tgif1
gene have been reported previously34. To delete Tgif1 in osteoblasts in vivo, mice
expressing the Cre recombinase under the control of the Osterix (Osx/SP7) pro-
moter (Osx-CreTg)36 or an 8 kb fragment of the murine Dentin matrix protein 1
(Dmp1) (Dmp1-CreTg)37 promoter were crossed with mice in which exons 2 and 3
of the Tgif1 gene are flanked by loxP sites (Tgif1fl/+)34. The resulting mice of the
genotype Osx-CreTg;Tgif1fl/+ were mated with Tgif1fl/+ mice to obtain Osx-CreTg;
Tgif1fl/fl mice with a conditional deletion of Tgif1 in osteoblasts. Osx-CreTg;Tgif1+/+
mice were used as control to exclude a non-specific phenotype caused by the Cre
expression. Since no bone phenotype was observed in Dmp1-Cre+mice, Dmp1-Cre-;
Tgif1fl/fl mice were used as controls. Mice carrying the Lrp5G170V/+ and Lrp5A213V/+
HBM mutations were obtained from Jackson Laboratories (Bar Harbor). Mice with
a conditional ablation of the PTHR1 controlled by a 10 kb fragment of the Dmp1
promoter (Dmp1-CreTg;PTHR1fl/fl) and mice expressing a constitutively active
PTHR1 (caPTHR1) regulated by an 8 kb fragment of the Dmp1 promoter (Dmp1-
caPTHR1) have been described previously48,49. For bone anabolic studies, a
recombinant fragment of human parathyroid hormone (PTH 1–34; 100 µg/kg of
body weight, Biochem) was administered intraperitoneally 5 times a week for
4 weeks. Anti-sclerostin antibody (Scl-Ab; kindly provided by Novartis and Mereo
BioPharma) was delivered intravenously at a concentration of 100 µg/kg once a
week for 4 weeks. All mouse strains used were maintained on a C57Bl/6J back-
ground. Sample sizes were determined according to the standards used in the field.
All experimental animals that were alive by the time of analysis were included in the
study. Mice of the same genotype were randomized to the treatment or control
group. Investigators were not blinded to the group allocation during the experiment,
but assessment of the outcome by bone histomorphometry was performed in a
blinded manner. The study received approval by the local authority for animal
welfare and experiments were conducted in compliance with all relevant ethical
regulations for animal testing and research.
Bone analyses. Mice were injected 7 and 2 days before sacrifice with calcein (20
mg/kg) and demeclocycline (20 mg/kg; both Sigma-Aldrich), respectively. Tibiae
and the fourth lumbar vertebral bodies (L4) were collected and fixed in 3.7%
phosphate-buffered saline (PBS)-buffered formaldehyde. For histomorphometric
analysis, tibiae and L4 were embedded in methylmethacrylate. Toluidine blue, von
Kossa and TRAP staining were performed using 4 µm sagittal sections. Quantita-
tive bone histomorphometric measurements were performed according to standard
protocols59 using an OsteoMeasure system (OsteoMetrics). Microcomputed
tomography (µCT) was used for bone analyses. Distal and midshaft femora were
analyzed using high-resolution µCT with a fixed isotropic voxel size of 15.6 µm (70
kV at 114 μA, 400 ms integration time; Viva80 micro-CT; Scanco Medical AG). All
analyses were performed on digitally extracted bone tissue using three-dimensional
distance techniques60.
Cell culture and ex vivo osteoblast differentiation assays. BMSCs were
obtained from three different mice. For each cell preparation, cells were plated at a
density of 10,000 cells/cm2 in 3 parallel cultures and cultured for 2 days in α-
minimum essential medium (α-MEM; Life Technologies) containing 10% fetal
bovine serum (FBS; Life Technologies) and 100 U/ml penicillin; 100 µg/ml strep-
tomycin (P/S; Life Technologies). Prior to RNA isolation, BMSCs from 3 parallel
cultures were pooled. The mouse stromal cell line ST2 was purchased from DSMZ
(Cat. No.: ACC 333) and maintained in RPMI-1640 medium (Life Technologies)
supplemented with 10% FBS and P/S. The rat osteosarcoma cell line UMR-106 was
purchased from ATCC (Cat. No.: CRL-1661) and maintained in Dulbecco's
modified Eagle's medium (DMEM; Life Technologies) with 10% FBS and P/S. The
osteocyte-derived OCY454 cell line has been reported previously61 and the
osteocyte-derived IDG-SW3 cell line was kindly provided by Dr. Lynda Bonewald.
Cells were maintained and expanded in culture dishes coated with rat tail type I
collagen (Corning) at 33 °C in complete medium (α-MEM, 10% FBS, and P/S) in
the presence of 10 U/ml interferon-gamma. Differentiation was performed at 37 °C
in the absence of interferon-gamma but with the addition of 0.2 mM L-ascorbic
acid (Sigma) and 5 mM β-glycerophosphate (Millipore). For calvarial osteoblast
cultures, calvariae were dissected from 1- to 3-day-old mice and digested
sequentially in α-MEM containing 0.1% collagenase and 0.2% dispase (both
Roche). Cell fractions 2 to 4 were combined and expanded in α-MEM containing
10% FBS and P/S. Osteoblast differentiation was induced by supplementing α-
MEM with 50 µg/ml L-ascorbic acid and 5 mM β-glycerophosphate. Osteoblast
differentiation was determined by alkaline phosphatase (ALP) and Alizarin Red
staining after fixing the cells in 4% neutrally buffered formaldehyde solution. For
ALP staining, cells were incubated with naphthol ASMX/Fast Blue (both from
Sigma-Aldrich) in Tris-HCl solution at pH 8.4 for 15 min at room temperature. To
detect matrix mineralization, Alizarin Red staining was performed with 40 mM
Alizarin Red S (AR-S; Sigma-Aldrich) solution at pH 4.2 for 10 min at room
temperature.
Long bone osteoblasts were isolated from femora and tibiae of 8–10-week-old
mice. After removing muscles in sterile PBS, bone marrow was flushed and bones
were cut in small pieces. Bone pieces were digested with 0.1% collagenase for 2 h at
37 °C and plated in α-MEM containing 10% FBS and P/S. Outgrowing osteoblasts
were detached with trypsin after 1 week and cultured until confluence (2–3 weeks).
Bone marrow macrophages (BMMs) were isolated from the bone marrow of 8-
week-old C57Bl/6J mice. Non-adherent cells were collected after 3 h of incubation
on plastic and cultured in α-MEM containing 10% FBS, P/S and macrophage
colony stimulating factor (100 ng/ml, PeproTech). For osteoblast–osteoclast co-
cultures, long bone osteoblasts were plated on 96-well plates and stimulated with
Vitamin D and Prostaglandin E2 (PGE2). One day later, BMMs were plated over
osteoblasts. Cultures were terminated after 5 days, fixed and stained with TRAP for
10 min at 37 °C. All reagents of the TRAP solution (Naphthol-ASMX-Phosphate,
Fast Red Violet LB-Salt and N,N-Dimethylformamid) were purchased from Sigma.
No cell line used is listed in the database of commonly misidentified cell lines
maintained by ICLAC. Cell lines used in this study have not been authenticated but
have been regularly tested for mycoplasma contamination using the PCR
Mycoplasma Test Kit (PromoKine).
Transfection of siRNAs and GapmeRs. Scrambled siRNAs and siRNAs targeting
mouse Sema3E and rat Tgif1 were purchased from Dharmacon. Scrambled Gap-
meRs and GapmeRs targeting rat Tgif1 were purchased from Qiagen. Long bone
osteoblasts were transfected using the NEON Transfection system (Thermo Fisher
Scientific). UMR-106 rat osteosarcoma cells were transfected using Lipofectamine
3000 (Life Technologies).
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DNA constructs and Luciferase assays. To mutate the Tgif1 promoter reporter
construct (kindly provided by S.J. Brandt), the AP1 binding site was modified using
the QuickChange II XL site-directed mutagenesis kit (Agilent). ST2 cells were
transfected with progressively truncated Tgif1 reporter constructs and a reporter
construct bearing a mutated AP1 binding site along with a Renilla reporter using
Lipofectamine reagent (Life Technologies) according to the supplier’s recom-
mendations. TopFlash β-catenin luciferase reporter (Addgene) containing 7
concatenated Tcf/Lef binding sites were co-transfected with a plasmid encoding
β-catenin as well as a Renilla luciferase reporter plasmid in calvarial osteoblasts
using the NEON transfection system. UMR-106 cells were transfected with the
hSOST-ECR5-luc reporter construct32 and a Renilla luciferase reporter plasmid
using Lipofectamine 3000. Luciferase assays were performed using the Dual-Glo
Luciferase Reporter Gene Assay System (Promega) according to the instructions
provided by the manufacturer. Firefly luciferase activity was normalized to Renilla
luciferase activity.
Gene expression analyses. Total RNA was isolated from mouse bones using
TRIzol reagent (Life Technologies) and from cultured cells using the RNeasy Plus
Mini kit (Qiagen) according to the manufacturer’s instructions. Complementary
DNA (cDNA) was synthesized from 1 µg of total RNA using the ProtoScript First
Strand cDNA Synthesis Kit (NEBioLabs). Quantitative real-time PCR (qRT-PCR)
was performed using SYBR Green (Bio-Rad). After normalization to TATA-
binding protein (Tbp) mRNA, relative expression levels and fold induction of each
target gene were calculated using the comparative CT (ΔΔCT) method. All
oligonucleotides used for qPCR analysis are listed in Supplementary Table 10.
RNA sequencing. Next-generation RNA sequencing was performed using three
distinct mouse bone marrow-derived mesenchymal stromal cell populations. Each
cell preparation was plated in three cultures and combined prior to analysis. Oligo
dT purified mRNA was used to generate cDNAs that were indexed using the
standard TruSeq Kits 12-Set A and 12-Set B on Illumina RTA version 1.17.21.3.
Read mapping was performed using a robust pipeline involving MAPRSeq v.1.2.1,
TopHat 2.0.6 alignment, HTSeq gene counting and expression normalization using
EdgeR62. Gene expression is expressed in reads per kilobase pair per million
mapped reads (RPKM).
Stable isotope labeling by amino acids in cell culture. Calvarial osteoblasts were
isolated from Tgif1−/− mice and control littermates followed by expansion for
6 days in non-differentiation medium. Cells were re-plated at matching cell
numbers for both genotypes not exceeding 80% confluence and cultured overnight.
SILAC was performed for 12 h in DMEM (Gibco) supplemented with 0.1% dia-
lyzed FBS lacking Met, Lys and Arg. Amino acid re-supplementation was achieved
using L-Lys and L-Arg (Gibco) for control osteoblasts and 13C6 L-Lys and 13C6
L-Arg (Thermo Scientific) for Tgif1−/− osteoblasts. Met was replaced by
L-Azidohomoalanin (AnaSpec) to allow for Click-iT-based enrichment. Condi-
tioned medium obtained from Tgif1−/− and control osteoblasts was combined
in a 1:1 ratio. Cell debris was removed by centrifugation and protease inhibitors
(Roche) were added to the solution. Next, newly synthesized proteins were
enriched from the conditioned medium using ultra centrifugal filters with a 3 kDa
cutoff (Amicon) and processed using the Click-iT Protein Enrichment-Kit
(Thermo Fisher) according to the manufacturer’s protocol.
Proteome analysis. For proteome analysis, proteins were subjected to in-solution
digestion with trypsin. Briefly, proteins were reduced with 100 mM dithiothreitol
dissolved in 100 mM NH4HCO3 at 50 °C for 10 min, followed by alkylation with
300 mM iodoacetamid dissolved in 100 mM NH4HCO3 for 30 min at room tem-
perature. Proteins were incubated with trypsin for 16 h at 37 °C. The digests were
acidified with formic acid (FA) and evaporated. For analysis of the tryptic peptides
with liquid chromatography coupled to mass spectrometry (LC-MS), samples were
dissolved in 20 µl 0.1% FA. LC-MS measurements were performed by injecting
the samples on a nano liquid chromatography system (Dionex UltiMate 3000
RSLCnano, Thermo Scientific) coupled via electrospray-ionization to a linear trap
quadrupole orbitrap mass spectrometer (Orbitrap Fusion, Thermo Scientific)63.
Peptides were separated by reversed phase chromatography (buffer A: 0.1% FA,
buffer B: 99.9% CAN, 0.1% FA; flow-rate: 250 nl/min; gradient: 2–30% B in 90
min). Every second, a MS scan was performed over a m/z range from 400 to 1500,
with a resolution of 120,000 FWHM (full width at half maximum) at m/z 200
(transient length= 256 ms, maximum injection time= 50 ms, automatic gain
control (AGC) target= 2e5). Analysis of fragmented peptide ions in the mass
spectrometer was carried out in data-dependent acquisition mode, using the top
speed mode, a HCD (higher-energy collisional dissociation) collision energy of
35%, an intensity threshold of 5e3 and an isolation width of 1.5m/z. Fragment
spectra were recorded in the ion trap (scan-rate= 66 kDa/s, maximum injection
time= 70 ms, AGC target= 1e4). LC-MS raw data were processed with Proteome
Discoverer 1.4 (Thermo Scientific). For identification, fragment spectra were
searched with Sequest HT against a mouse database (SwissProt, www.uniprot.org,
downloaded 1.5.2014). The searches were performed using the following para-
meters: precursor mass tolerance was set to 10 parts per million (ppm) and frag-
ment mass tolerance was set to 0.5 Da. Furthermore, two missed cleavages were
allowed and a carbamidomethylation on cysteine residues as a fixed modification.
An oxidation of methionine residues and a 13C6-label on both lysine and arginine
residues were allowed as variable modifications. Peptides were identified with a
false discovery rate of 1% using percolator and proteins were kept as correctly
identified if at least two unique peptides were identified. For SILAC quantitation,
event detector and precursor ion quantifier algorithms of Proteome Discoverer
were used64. A mass variability of 2 ppm and a 0.2 min retention time tolerance
on precursor ion pairs were used and protein ratios were based on the median
peptide ratio. At least two isotopic peaks were required for inclusion, as well as
a minimal signal to noise level of three.
Immunoblotting. Cells were lysed in low salt mRIPA buffer (pH 7.5) containing
50 mM Tris base, 150 mM NaCl, 0.5% Nonidet P-40, 0.25% sodium deoxycholate
and complete protease and phosphatase inhibitors (Roche). Lysates were separated
on 12% polyacrylamide gels and subjected to immunoblot blot analysis. Immu-
noblots were incubated overnight at 4 °C with primary antibodies against Tgif1
(1:1000, rabbit monoclonal, Abcam, Cat. No: ab52955), Tgif2 (1:500, rabbit poly-
clonal, Millipore, Cat. No: 09-718), Sema3E (1:1000, goat polyclonal, R&D Systems,
Cat. No: AF3239), pCREB (1:500, rabbit monoclonal, Cell Signaling, Cat. No:
87G3), Mef2c (1:1000, rabbit monoclonal, Abcam, Cat. No: 197070) and Actin
(1:5000, mouse monoclonal, Millipore, Cat. No: MAB1501). Peroxidase-labeled
anti-rabbit or anti-mouse secondary antibodies (1:10,000, Promega, Cat. No:
W401B, W402B) were used to visualize bands using the Clarity Western ECL
Substrate (Bio-Rad). Immunoblot images were acquired using the ChemiDoc
imaging system and Image Lab software (Bio-Rad). Unprocessed scans of the
most important immunoblots are supplied in the source data file.
Immunohistochemistry. To determine sclerostin expression in mouse bones, mice
were sacrificed 24 h after the last PTH injection and tibiae were fixed as described
above. Bones were decalcified in 10% EDTA (pH 7.4) for 2 weeks, dehydrated,
embedded in paraffin and cut in 4 µm sections. Staining for sclerostin was
performed using an anti-sclerostin antibody (1:50, goat polyclonal, R&D Systems,
Cat. No: AF1589).
ELISA. Enzyme-linked immunosorbent assay (ELISA) was used for quantitative
determination of RANKL and OPG (both Immunodiagnostics systems) in mouse
serum. All procedures were performed according to the manufacturer’s guidelines.
Chromatin immunoprecipitation. Putative Tgif binding sites in the SOST
promoter were identified using the online platform ALGGEN-PROMO. ChIP
was performed using the A/G MAGNA ChIP kit (Millipore, Cat. No: 17-10085)
according to the manufacturer’s instruction. Briefly, 5 × 106 cells of the osteocyte-
like cell line OCY454 were plated into 15 cm2 dishes to differentiate for 2 weeks at
37 °C. After 2 h of treatment with either PTH (100 nM) or vehicle, crosslinking was
performed using 1% formaldehyde for 10 min, followed by quenching for 5 min
with glycin. After chromatin isolation, DNA was sheared into fragments ranging
from 100 bp to 500 bp by 30 cycles of high-frequency sonication using a Bior-
aptorPlus. ChIP was performed using 5 μg of rabbit polyclonal anti-Tgif1 antibody
(Santa Cruz Biotechnology, Cat. No: sc9084) or 5 µg of a ChIP-grade polyclonal
rabbit anti-IgG antibody (Abcam, Cat. No: ab37415). The amount of DNA pulled
down was quantified by qPCR. All Ct values exceeding 34 were excluded from the
analysis. ChIP-qPCR data were first normalized to the input of each precipitation
using the formula (2(Ct 100% input−Ct sample)), followed by normalization to the
IgG control. Rarα was used as positive control55. The oligonucleotides used for
amplifying the DNA fragments representing the 11 Tgif1 binding sites are listed
in Supplementary Table 10. A region nearby the transcriptional start site of the
Sost gene was used as negative control.
Statistical analyses. Quantitative data are presented as mean ± s.e.m. unless
otherwise described. Parametric data were analyzed using an appropriate two-tailed
Student's t-test when two groups were compared. A one-way analysis of variance
(ANOVA) was used when more than two groups were compared, followed by
Newman–Keuls post-hoc analysis to compare the groups. Probability values were
considered statistically significant at p < 0.05. Experiments were repeated at least
three times as biological replicates with minimum of two technical replicates.
No sample size calculations were performed but the number of mice analyzed
in animal studies was determined in agreement with the standards in the field.
Variation between groups was similar in all cases. Statistical analyses were
performed using GraphPad Prism software.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Next generation RNA-sequencing data that support the findings of this study have
been deposited at the Center for Biotechnology Information with the accession code
GSE89132. The mass spectrometry proteomics data that support the findings of this
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study have been deposited to the ProteomeXchange Consortium via the PRIDE partner
repository with the dataset identifier PXD012303.
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